India's leading biotechnology company, Biocon Ltd has reported a fall of 15 per cent in net profit in the quarter till December 2011 mainly due to lower licensing income.

Biocon, which is based in Bangalore, has said that its consolidated net profit fell to 848 million rupees in the third quarter till December 2011 compared to 1.01 billion rupees in the same period previous year.

The total revenue for the company increased 3 per cent in October-December quarter. The company's licensing fees and income fell to 292 million rupees from 768 million rupees in the previous year.

Bangalore based biotechnology major, Biocon is optimistic about the branded formulations business, which recorded a strong growth of 37 percent in the half of the current fiscal year.

Kiran Mazumdar Shaw, chairman and managing director said "We recently launched a reusable insulin delivery device which will further propel sales in the branded formulations vertical."

Indian biotechnology giant, Biocom has reported a fall of 4 percent in its quarterly profit mainly due to increases expenses on higher energy costs and wages.

The company said that its consolidated net profit fell to 857 million rupees in the second quarter of the financial year compared to 892.2 million in the year ago period. However, the company sees an opportunity in strong demand from branded formulations.

The net profit of biotechnology company Biocon decreased by 9% in a year amounting to Rs 70.05 crore, but the company witnessed an increase in the sales by 10% amounting to Rs 441.68 crore. The low income earned by the company had affected the share prices of the company, marked by a fall of 2.8% at Rs 360.15 on NSE.

Bangalore, April 28 : Indian biopharma major Biocon Ltd posted consolidated net profit of Rs. 101 crore for fourth quarter (January-March) of fiscal 2010-11, registering 25 percent year-on-year (YoY) growth.

In a regulatory filing Thursday, the country's leading biotech firm said consolidated revenue for the quarter (Q4) under review, however, grew by eight percent YoY to Rs. 717 crore from Rs. 666 crore same quarter year ago.

Technical analyst D Prasad maintained 'buy' rating on Biocon Industries Limited stock to achieve a target of Rs 394.

According to analyst, the stock can be purchased above Rs 381 with a stop loss of Rs 373.

The stock of the company, on January 19, closed at Rs 377.50 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 464.60 and a low of Rs 256 on BSE.

Current EPS & P/E ratio stood at 16.37 and 23.70 respectively.

Biocon has announced its outcomes for the three month period ended December 2010.

Stock market analyst Salil Sharma has maintained 'buy' rating on Biocon Ltd stock with a target of Rs 354

According to analyst, the interested investors can buy the stock with stop loss of Rs 340.

The stock of the company, on Sep 03, closed at Rs 345.50 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 356 and a low of Rs 230 on BSE.

Current EPS & P/E ratio stood at 15.62 and 22.22 respectively.

Biocon has recorded a net profit of Rs 77 crore for April-June quarter of this fiscal (20010-11), recording year-on-year (YoY) expansion of 33%as against Rs 58 crore in the same period of last year.

In a regulatory filing, the top biotechnology firm stated that its total income grew by 33%YoY to Rs 672 crore for the three month period ended June 2010 as against Rs 505 crore during the same period of 2009-10.

The company's EBITDA (earnings before interest, taxes, depreciation and amortization) at Rs. 141 crore grew 27 percent YoY from Rs. 111 crore year ago.

Stock market analyst Salil Sharma is of the view that investors can 'buy' Reliance India Ltd stock with a short term target of Rs 1060.

According to analyst, the investors can buy the stock with stop loss of Rs 1035.

Today, the stock of the company opened at Rs 1045 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 1186.15 and a low of Rs 875.50 on BSE.

Current EPS & P/E ratio stood at 49.31 and 21.01 respectively.

RIL has paid approx Rs 12,382 crore of unsecured loans during the last fiscal, lessening its arrears by about 15.5%.

The leading Biotechnology firm of India, Biocon has announced it's fourth quarter financial results. Biocon is basically known for its outlined services on diabetes, cancer and auto-immune diseases etc. The Bio firm has managed to register an impressive net profit. The company has made a profit of Rs 80.6 crore in this quarter.

During January to March this year the net profit has raised sharply as there was a huge increases in revenue. There was a forex loss of Rs 41.4 crore as well.

Stock market analysts have maintained 'buy' rating on Biocon Ltd with an intraday target of Rs 299.

According to them, interested traders can purchase the stock with a strict stop loss of Rs 289.

If the bourses remain on the positive track, then the stock price will hit a target above Rs 305.

Shares of the company, on Wednesday (Dec 09), closed at Rs 293.20 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 298.40 and a low of Rs 90.10 on BSE.

Biocon Chairperson Kiran Mazumdar Shaw told people not to be afraid of breast cancer even though its prevalence has been developing.

She added that breast cancer was no more a killer disease, and was curable without any difficulty.

Mazumdar was speaking on the opening of the Mazumdar Shaw Cancer Centre's 30-day long programme that was launched to make people aware about the need for an early detection via medical examinations.

She also said that a decade ago, carcinoma was known as a killer disease, but not anymore.

Stock market analysts are of the view that investors can sell Biocon Ltd stock with a target price between Rs 250-245.

According to them, investors can sell the stock below Rs 253 with a strict stop loss of Rs 257.

If the stock fell below Rs 240, it may see more weakness.

Today (Oct 28), the stock opened at Rs 256 on the Bombay Stock Exchange (BSE). Current EPS & P/E ratio stood at 7.91 and 32.49 respectively. The share price has seen a 52-week high of Rs 284.40 and a low of Rs 86.55 on BSE.

Mumbai, Oct 22 : Bangalore-based biotech major Biocon posted a net profit of $13.85 million (Rs. 62.36 crore) in the quarter ended Sep 30 compared to $7.45 million (Rs. 33.5 crore) earned in the like period of the previous year, the company said in a filing Thursday.

The company's total income increased to $6.96 million (Rs. 312.44 crore) in the period under review from $59.6 million (Rs. 268 crore) during the corresponding quarter last year, Biocon told the Bombay Stock Exchange in a regulatory statement.

Gulf Oil Corporation, leading Hinduja Group Company, has announced that its arm known as IDL Speciality Chemicals has inked a contract with Biocon.

Under the contract, IDL Speciality Chemicals will market its Active Pharmaceuticals Ingredients (API) undertaking.

The financial details of the contract have not been revealed by the company. API is the basic raw material which is utilized in making medicines.     

Gulf Oil Corporation is basically a lubricant company, which also engages in explosives, consult dealing in mining as well as infrastructure contracts, specialty chemicals dealing in bulk drugs and pharmaceutical sector.

Biocon has informed that the company has signed an exclusive agreement with Amylin Pharmaceuticals to jointly develop, commercialize and manufacture a novel Peptide Hybrid drug to be used for treatment of Diabetes.

According to an official communiqué,  Amylin and Biocon would collaborate to develop the therapeutic potential of the compound and share development costs.    

Biocon Ltd, a leading Bangalore-based biotechnology firm has reported four-fold jump in its consolidated net profit at Rs 57 crore for the quarter ended June 30, 2009 against Rs 15 crore in the same period ended June 2008.

Company's total income in the reporting quarter increased to Rs 505 crore from Rs 276 crore in the same quarter previous fiscal.

On a standalone basis, the company has clocked a net profit of Rs 47 crore up 58.44% during quarter under review as compared to Rs 30 crore in the same period last fiscal.

The Rs 1,673-crore Bangalore-based biotech major, Biocon Limited, has signed a deal with US based Mylan Inc to collaborate in the field of generic biologic drugs. Both the firms will join hands for developing, manufacturing and commercializing biological compounds to achieve a leading position in the emerging generic drug industry, by virtue of their highly complementary capabilities in their respective domains.

Stock market analyst Ashwani Gujral has maintained ‘Buy’ rating on Biocon to achieve a target between Rs 260- Rs 265 in 1-2 trading sessions.

According to Mr. Gujral, interested traders can buy the stock with a strict stop loss of Rs 210.

Shares of the company, on Friday (June 26), closed at Rs 226.75 on the Bombay Stock Exchange (BSE). Current EPS & P/E ratio stood at 5.59 and 41.70 respectively. The share price has seen a 52-week high of Rs 234.70 and a low of Rs 86.55 on BSE.